Solventum Co. (NYSE:SOLV) Shares Bought by Mayar Capital Ltd.

Mayar Capital Ltd. increased its holdings in Solventum Co. (NYSE:SOLV) by 187.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 30,290 shares of the company’s stock after acquiring an additional 19,739 shares during the quarter. Solventum makes up 2.6% of Mayar Capital Ltd.’s portfolio, making the stock its 10th biggest position. Mayar Capital Ltd.’s holdings in Solventum were worth $2,001,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Modus Advisors LLC bought a new stake in shares of Solventum in the 4th quarter worth about $25,000. Stonebridge Financial Group LLC acquired a new position in Solventum in the fourth quarter worth about $26,000. True Wealth Design LLC increased its holdings in Solventum by 23,550.0% in the third quarter. True Wealth Design LLC now owns 473 shares of the company’s stock valued at $33,000 after buying an additional 471 shares during the last quarter. Crews Bank & Trust acquired a new stake in Solventum during the fourth quarter valued at approximately $32,000. Finally, Prospera Private Wealth LLC bought a new position in Solventum during the 3rd quarter worth approximately $35,000.

Solventum Trading Up 2.9 %

Solventum stock opened at $77.96 on Friday. Solventum Co. has a 12-month low of $47.16 and a 12-month high of $85.92. The stock has a market capitalization of $13.47 billion and a PE ratio of 28.35. The firm has a 50 day simple moving average of $73.65 and a 200-day simple moving average of $70.63. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on SOLV shares. Morgan Stanley increased their price objective on shares of Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a research note on Wednesday. The Goldman Sachs Group raised their target price on Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a research note on Monday, March 3rd. Piper Sandler upped their price target on shares of Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research report on Friday, February 28th. Wells Fargo & Company lifted their price objective on shares of Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a research report on Friday, February 28th. Finally, Bank of America upped their target price on shares of Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 26th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $79.86.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.